Impact of frequent hemodialysis on anemia management: Results from the Frequent Hemodialysis Network (FHN) Trials

Nephrology Dialysis Transplantation

Volumn 28, Issue 7, 2013, Pages 1888-1898

  Ornt, Daniel B ^a   Larive, Brett ^b   Rastogi, Anjay ^c   Rashid, Mohamad ^c   Daugirdas, John T ^d   Hernandez, Ann ^c   Tamura, Manjula Kurella ^e   Suri, Rita S ^f   Levin, Nathan W ^g   Kliger, Alan S ^h  

^a ROCHESTER INSTITUTE OF TECHNOLOGY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g RENAL RESEARCH INSTITUTE   (United States)

^h YALE UNIVERSITY   (United States)

Author keywords

Anemia; Erythropoietin; Frequent; Hemodialysis; Nocturnal

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TRANSFERRIN;

ADULT; ANEMIA; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANEMIA; ERYTHROPOIETIN; FREQUENT; HEMODIALYSIS; NOCTURNAL;

ANEMIA; COMBINED MODALITY THERAPY; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS;

EID: 84884507501     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs593     Document Type: Article

References (22)

1. Folkert VW, Meyer TW, Hostetter TH. Anemia therapy in ESRD: time to move on. Clin J Am Soc Nephrol 2010; 5: 1163-1164
2. Puñal J, Lema LV, Sanhez-Guisande D et al. Clinical effectiveness and quality of life of conventional haemodialysis versus short daily haemodialysis: a systematic review. Nephrol Dial Transplant 2008; 23: 2634-2646
3. Walsh M, Culleton B, Tonelli M et al. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int 2005; 67: 1500-1508
4. Culleton BF, Walsh M, Klarenbach SW. Effect of frequent nocturnal hemodialysis vs. conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007; 298: 1291-1299
5. Rao M, Muirhead N, Klarenbach S et al. Management of anemia with quotidian hemodialysis. Am J Kidney Dis 2003; 42 (Suppl. 1): S18-S23
6. Ayus JC, Mizani MR, Achinger SG et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005; 16: 2778-2788
7. Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis 2004; 44: 715-719
8. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif 2004; 22: 112-123
9. Suri RS, Garg AX, Chertow GM et al. Frequent hemodialysis network (FHN) randomized trials: study design. Kidney Int 2007; 71: 349-359
10. Chertow GM, Levin NW, Beck GJ et al. Effects of frequent incenter hemodialysis: the frequent hemodialysis network daily trial. N Engl J Med 2010; 363: 2287-2300
11. Rocco MV, Lockridge RS, Beck GJ et al. The effects of frequent nocturnal home hemodialysis: the frequent hemodialysis network nocturnal trial. Kidney Int 2011; 80: 1080-1091
12. Gobin J, Cernii A, McLean R et al. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study. Clin Drug Investig 2011; 31: 113-120
13. KDOQI; National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006; 47 (Suppl 3): S16-S85
14. Jennrich RI, Schluchter MD. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986; 42: 805-820
15. Jensen JL. Use of the geometric average for effective permeability estimation. Math. Geol. 1991; 23: 833-840
16. Kanbay M, Perazella MA, Kasapoglu B et al. Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif 2010; 29: 1-12
17. Kaysen GA, Greene T, Larive B et al. The effect of frequent hemodialysis on nutrition and body composition: frequent hemodialysis network trial. Kidney Int 2012; 82: 90-99
18. Singh AK, Szczech L, Tang KL et al. CHOIR investigators: correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
19. Pfeffer MA, Burdmann EA, Chen CY et al. TREAT investigators: a trial of darbopoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
20. Arbor Research Collaborative for Health. DOPPS Practice Monitor. http://www.dopps.org/DPM/Default.aspx (4 January 2013, date last accessed)
21. Kovesdy CP, Kalantar-Zadeh K. Iron therapy in chronic kidney disease: current controversies. J Ren Care 2009; 35(Suppl 2): 14-24
22. Locatelli F, Martin-Malo A, Hannedouche T et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645-654